Related Experiment Video
Updated: Jun 6, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Epigenetic biomarker for preeclampsia-associated preterm birth and potential preventative medicine
Eric E Nilsson1, Paul Winchester2, Cathy Proctor2
1Center for Reproductive Biology, School of Biological Sciences, Washington State University, Pullman, WA 99164-4236, United States.
Insights
Researchers identified 389 DNA methylation differences in maternal buccal cells that may predict preeclampsia-induced preterm birth (PTB). This epigenetic biomarker shows potential for early detection and preventative strategies, achieving 78% accuracy in preliminary validation.
Area of Science:
- Epigenetics
- Maternal Health
- Biomarker Discovery
Background:
- Preterm birth (PTB) affects over 10% of births, with preeclampsia being a major subtype.
- Current clinical methods lack reliable biomarkers to predict preeclampsia-induced PTB.
- Epigenetic alterations, specifically DNA methylation, are explored as potential predictive markers.
Purpose of the Study:
- To investigate DNA methylation differences in maternal buccal cells as potential biomarkers for preeclampsia-induced PTB.
- To identify specific differential DNA methylation regions (DMRs) associated with preeclampsia.
- To assess the preliminary accuracy of these DMRs as a predictive biomarker.
Main Methods:
- Comparison of DNA methylation patterns in maternal buccal cells from non-preeclampsia term births versus preeclampsia PTBs.
- Genome-wide analysis to identify differential DNA methylation regions (DMRs).
- Cross-validation analysis for preliminary accuracy assessment.
Main Results:
- Identified 389 genome-wide DMRs associated with preeclampsia, predominantly in low CpG density regions.
- Found a 15% overlap with previously identified PTB buccal cell epigenetic biomarkers, highlighting unique DMRs for preeclampsia.
- DMRs showed associations with the PI3K-Akt signaling pathway and metabolic gene families, including phospholipid signaling.
- Preliminary validation achieved 78% accuracy for DMRs as a predictive biomarker.
Conclusions:
- The study provides proof of concept for an epigenetic biomarker for preeclampsia-induced PTB using maternal buccal cells.
- Identified DMRs offer potential for early detection and clinical management of preeclampsia.
- Further clinical trials in early pregnancy are needed to validate these findings and enable preventative medicine approaches.
Abstract:
Preterm birth (PTB) has dramatically increased within the population (i.e. >10%) and preeclampsia is a significant sub-category of PTB. Currently, there are no practical clinical parameters or biomarkers which predict preeclampsia induced PTB. The current study investigates the potential use of epigenetic (DNA methylation) alterations as a maternal preeclampsia biomarker. Non-preeclampsia term births were compared to preeclampsia PTBs to identify DNA methylation differences (i.e. potential epigenetic biomarker). Maternal buccal cell cheek swabs were used as a marker cell for systemic epigenetic alterations in the individuals, which are primarily due to environmentally induced early life or previous generations impacts, and minimally impacted or associated with the disease etiology or gestation variables. A total of 389 differential DNA methylation regions (DMRs) were identified and associated with the presence of preeclampsia. The DMRs were genome-wide and were predominantly low CpG density (<2 CpG/100 bp). In comparison with a previous PTB buccal cell epigenetic biomarker there was a 15% (60 DMR) overlap, indicating that the majority of the DMRs are unique for preeclampsia. Few previously identified preeclampsia genes have been identified, however, the DMRs had gene associations in the P13 K-Akt signaling pathway and metabolic gene family, such as phospholipid signaling pathway. Preliminary validation of the DMR use as a potential maternal biomarker used a cross-validation analysis on the samples and provided 78% accuracy. Although prospective expanded clinical trials in first trimester pregnancies and clinical comparisons are required, the current study provides the potential proof of concept a preeclampsia epigenetic biomarker may exist. The availability of a preeclampsia PTB maternal susceptibility biomarker may facilitate clinical management and allow preventative medicine approaches to identify and treat the preeclampsia condition prior to its occurrence.
More Related Videos
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Teratogenicity